Pharma BD Deal Intelligence
Eisai got its oncology sales force and CTCL foothold, but every acquired drug ended up divested, withdrawn, or marginal within a decade
Full analysis, sources & comparables →Eisai paid Ligand $205M cash for four oncology products (Ontak, Targretin capsules and gel, Panretin gel); Ligand framed the divestiture as part of refocusing…
Sales reshape Ligand as the company divests its oncology portfolio to Eisai and other product lines to refocus the business.
Eisai bought rights to Targretin and three other anti-cancer products from Ligand in 2006; the products served narrow CTCL and Kaposi's sarcoma indications and…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Acquired four oncology products: Ontak, Targretin (capsule and gel), Panretin
Eisai got its oncology sales force and CTCL foothold, but every acquired drug ended up divested, withdrawn, or marginal within a decade
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Eisai Co., Ltd. / Ligand Pharmaceuticals (oncology product portfolio) (this deal) | 2006 | $205M | 41 |
| Eisai Co., Ltd. / MGI Pharma Inc. | 2007 | $3.9B | 36 |
| Eisai Co., Ltd. / SEED Therapeutics Inc. | 2024 | $1.5B | — |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Crucell N.V. / Berna Biotech AG | 2006 | $450M | 85 |
| Lonza Group AG / Cambrex Bioproducts and Biopharma businesses | 2006 | $460M | 83 |
| Reckitt Benckiser plc / Boots Healthcare International | 2006 | $3.4B | 82 |
← Browse all deals · How we score deals
More: 2006 deals · Eisai Co., Ltd. deals